34569964|t|Modeling Sympathetic Hyperactivity in Alzheimer's Related Bone Loss.
34569964|a|BACKGROUND: A significant subset of patients with Alzheimer's disease (AD) exhibit low bone mineral density and are therefore more fracture-prone, relative to their similarly aged neurotypical counterparts. In addition to chronic immune hyperactivity, behavioral dysregulation of effector peripheral sympathetic neurons-which densely innervate bone and potently modulate bone remodeling-is implicated in this pathological bone reformation. OBJECTIVE: Thus, there exists a pressing need for a robust in vitro model which allows interrogation of the paracrine interactions between the putative mediators of AD-related osteopenia: sympathetic neurons (SNs) and mesenchymal stem cells (MSCs). METHODS: Toward this end, activated SN-like PC12 cells and bone marrow derived MSCs were cultured in poly(ethylene glycol) diacrylate (PEGDA) hydrogels in the presence or absence of the AD-relevant inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) under mono- and co-culture conditions. RESULTS: PC12s and MSCs exposed separately to TNF-alpha displayed increased expression of pro-inflammatory mediators and decreased osteopontin (OPN), respectively. These data indicate that TNF-alpha was capable of inducing a dysregulated state in both cell types consistent with AD. Co-culture of TNF-alpha-activated PC12s and MSCs further exacerbated pathological behaviors in both cell types. Specifically, PC12s displayed increased secretion of interleukin 6 relative to TNF-alpha stimulated monoculture controls. Similarly, MSCs demonstrated a further reduction in osteogenic capacity relative to TNF-alpha stimulated monoculture controls, as illustrated by a significant decrease in OPN and collagen type I alpha I chain. CONCLUSION: Taken together, these data may indicate that dysregulated sympathetic activity may contribute to AD-related bone loss.
34569964	9	34	Sympathetic Hyperactivity	Disease	MESH:D006948
34569964	38	49	Alzheimer's	Disease	MESH:D000544
34569964	58	67	Bone Loss	Disease	MESH:D001847
34569964	105	113	patients	Species	9606
34569964	119	138	Alzheimer's disease	Disease	MESH:D000544
34569964	140	142	AD	Disease	MESH:D000544
34569964	200	208	fracture	Disease	MESH:D050723
34569964	299	319	immune hyperactivity	Disease	MESH:D006948
34569964	674	676	AD	Disease	MESH:D000544
34569964	685	695	osteopenia	Disease	MESH:D001851
34569964	802	806	PC12	CellLine	CVCL:0481
34569964	859	891	poly(ethylene glycol) diacrylate	Chemical	MESH:C437167
34569964	893	898	PEGDA	Chemical	MESH:C437167
34569964	944	946	AD	Disease	MESH:D000544
34569964	956	968	inflammatory	Disease	MESH:D007249
34569964	978	1005	tumor necrosis factor alpha	Gene	24835
34569964	1007	1016	TNF-alpha	Gene	24835
34569964	1066	1071	PC12s	CellLine	CVCL:U609
34569964	1103	1112	TNF-alpha	Gene	24835
34569964	1151	1163	inflammatory	Disease	MESH:D007249
34569964	1188	1199	osteopontin	Gene	25353
34569964	1201	1204	OPN	Gene	25353
34569964	1246	1255	TNF-alpha	Gene	24835
34569964	1336	1338	AD	Disease	MESH:D000544
34569964	1354	1363	TNF-alpha	Gene	24835
34569964	1374	1379	PC12s	CellLine	CVCL:U609
34569964	1466	1471	PC12s	CellLine	CVCL:U609
34569964	1505	1518	interleukin 6	Gene	24498
34569964	1531	1540	TNF-alpha	Gene	24835
34569964	1658	1667	TNF-alpha	Gene	24835
34569964	1745	1748	OPN	Gene	25353
34569964	1893	1895	AD	Disease	MESH:D000544
34569964	1904	1913	bone loss	Disease	MESH:D001847
34569964	Association	MESH:D000544	24835
34569964	Negative_Correlation	24835	25353
34569964	Positive_Correlation	MESH:D007249	24835

